SCHEMBL2210496

SCHEMBL2210496

COc1ccc(Cn2c(-c3ccc(Cl)cc3)c3c(=O)n(CCN4CCOCC4)[nH]c3cc2=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX4 Q9NPH5 6/20 0.51
SMN1; SMN2 Q16637 1/20 0.44
PDE5A O76074 2/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
MAPK1 P28482 1/20 0.42
SLC2A1 P11166 2/20 0.41
USP2 O75604 1/20 0.40
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
HIF1A Q16665 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
CYBB P04839 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2208802 0.93 NOX4 (0.52) NOX4SMN1; SMN2ALDH1A1MAPTMAPK1
SCHEMBL2211022 0.92 ALDH1A1 (0.50) NOX4ALDH1A1MAPK1SLC2A1USP2
SCHEMBL2212766 0.85 NOX4 (0.61) NOX4ALDH1A1USP2CYP1A2TSHR
SCHEMBL2209346 0.85 NOX4 (0.53) NOX4SMN1; SMN2ALDH1A1MAPTHSD17B10
SCHEMBL1302694 0.84 MEN1 (0.44) NOX4ALDH1A1MAPTMAPK1USP2
SCHEMBL2211354 0.83 NOX4 (0.67) NOX4ALDH1A1MAPTMAPK1KDM4E
SCHEMBL2213956 0.83 NOX4 (0.51) NOX4ALDH1A1MAPTCYP1A2CASP1
SCHEMBL2210536 0.81 NOX4 (0.47) NOX4MAPK1ACHE
SCHEMBL2214189 0.81 NOX4 (0.62) NOX4ALDH1A1MAPK1USP2CYP1A2
SCHEMBL2211527 0.80 NOX4 (0.49) NOX4ALDH1A1MAPTUSP2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 EP claimed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US claimed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 US claimed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 US claimed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US claimed
EP-2342203-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GenKyoTex SA (CH) 2011-07-13 EP claimed
WO-2010035220-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 WO claimed
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 EP disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US disclosed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 US disclosed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 US disclosed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 US disclosed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US disclosed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US disclosed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US disclosed
EP-2342203-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GenKyoTex SA (CH) 2011-07-13 EP disclosed
WO-2010035220-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 WO disclosed
WO-2010035220-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB NOX4 2/4885SMN1; SMN2 2521/4885PDE5A 348/4885
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB NOX4 2/4885SMN1; SMN2 2521/4885PDE5A 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.